Weight Loss

---

Semaglutide is an antidiabetic medication used for the treatment of type 2

diabetes and long-term weight management. Semaglutide acts like

human glucagon-like peptide-1 in that it increases insulin secretion,

thereby increasing sugar metabolism. It works by helping the pancreas to

release the right amount of insulin when blood sugar levels are high.

Weight loss may result from GLP-1’s reduction of appetite and slowing

down digestion. This was a global study of nearly 2000 individuals with a

BMI of 30 or greater, or BMI of 27 or greater and coexistent hypertension,

dyslipidemia, sleep apnea, or cardiovascular disease. The treatment group

received subcutaneous injections of semaglutide, the control a placebo

injection; both groups received “lifestyle interventions.

” The outcomes of

interest were weight loss as measured as a percent change from baseline

and achieving a 5% or greater reduction in body weight over 68 weeks.

***Also available compound  with  B12

Tirzepatide (Mounjaro) is a novel dual agonist peptide that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It works by increasing insulin available and decreasing glucagon (a hormone that controls the amount of glucose made by the liver) available in the body. 

Weight Loss Benefits:

Appetite Suppression: Tirzepatide's activation of GLP-1 receptors in the hypothalamus, a region of the brain responsible for regulating appetite, results in increased satiety and decreased hunger. This suppression of appetite is one of the primary mechanisms by which tirzepatide contributes to weight loss.

Delayed Gastric Emptying: GLP-1 receptor activation by tirzepatide also slows down gastric emptying, which in turn reduces the rate at which nutrients are absorbed. This effect can help individuals feel fuller for longer periods, leading to a reduced caloric intake and subsequent weight loss.

Improved Lipid Metabolism: Tirzepatide's action on GIP receptors found in adipose tissue, liver, and other peripheral tissues helps enhance lipid metabolism. This leads to a decrease in fat storage and an increase in the utilization of stored fat for energy, contributing to weight loss.

Enhanced Glucose Homeostasis: As a dual GIP and GLP-1 receptor agonist, tirzepatide improves glucose homeostasis by stimulating insulin secretion in response to food intake and suppressing glucagon secretion. This improved glucose regulation can contribute to weight loss by promoting a more efficient use of energy sources and reducing the risk of insulin resistance and weight gain.

Reduced Inflammation: Studies have suggested that tirzepatide may reduce inflammation, which is often associated with obesity and metabolic dysfunction. By lowering inflammation, tirzepatide may help create a more favorable metabolic environment for weight loss.

The weight loss effects of tirzepatide have been demonstrated in clinical trials involving patients with type 2 diabetes. In these trials, patients experienced significant reductions in body weight compared to those receiving other antidiabetic medications or placebo. The dual agonist mechanism of tirzepatide, targeting both GLP-1 and GIP receptors, appears to be a key factor in its potent weight loss effects.